Comparative bioequivalence study of sodium zirconium cyclosilicate (SZC-9) in the forms of 5 and 10 g sachets vs brand medicine (Lokelma made by AztraZeneca)
Not Applicable
- Conditions
- E87.5Hyperkalaemia.Hyperkalaemia
- Registration Number
- IRCT20130313012810N11
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
patients with hyperkalemia
Volunteers aged 22-75 years
male and female
Exclusion Criteria
History of diseases affecting the digestive system
Taking any medication at least 1 week before the start of the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of potassium. Timepoint: Measurement of blood potassium at the beginning of the study (before the start of the intervention), 2, 6, 12, 24, 36, and 48 hours after receiving the drug by the patients. Method of measurement: Biorexfars potassium kit.
- Secondary Outcome Measures
Name Time Method